Florida International University

FIU Digital Commons
All Faculty

2-17-2006

Is it safe? Talking to teens with HIV/AIDS about
death and dying: a 3-month evaluation of Family
Centered Advance Care (FACE) planning ?
anxiety, depression, quality of life
Maureen E. Lyon
Children’s National Medical Centerand George Washington Schoolof Medicine and Health Sciences,

Patricia A. Garvie
St Jude Children’s Research Hospital

Linda Briggs
GundersenLutheran Medical Foundation, Inc.

Jianping He
Children’sResearch Institute

Robert Malow
Health Promotion and Disease Prevention, FloridaInternational University
See next page for additional authors

Follow this and additional works at: https://digitalcommons.fiu.edu/all_faculty
Recommended Citation
Lyon, Maureen E.; Garvie, Patricia A.; Briggs, Linda; He, Jianping; Malow, Robert; D'Angelo, Lawrence J.; and McCarter, Robert, "Is it
safe? Talking to teens with HIV/AIDS about death and dying: a 3-month evaluation of Family Centered Advance Care (FACE)
planning ? anxiety, depression, quality of life" (2006). All Faculty. 15.
https://digitalcommons.fiu.edu/all_faculty/15

This work is brought to you for free and open access by FIU Digital Commons. It has been accepted for inclusion in All Faculty by an authorized
administrator of FIU Digital Commons. For more information, please contact dcc@fiu.edu.

Authors

Maureen E. Lyon, Patricia A. Garvie, Linda Briggs, Jianping He, Robert Malow, Lawrence J. D'Angelo, and
Robert McCarter

This article is available at FIU Digital Commons: https://digitalcommons.fiu.edu/all_faculty/15

HIV/AIDS - Research and Palliative Care

Dovepress
open access to scientific and medical research

o R i g i n al r e s e arch

Open Access Full Text Article

Is it safe? Talking to teens with HIV/AIDS about
death and dying: a 3-month evaluation of Family
Centered Advance Care (FACE) planning –
anxiety, depression, quality of life
This article was published in the following Dove Press journal:
HIV/AIDS - Research and Palliative Care
17 February 2010
Number of times this article has been viewed

Maureen E Lyon 1
Patricia A Garvie 2
Linda Briggs 3
Jianping He 4
Robert Malow 5
Lawrence J D’Angelo 1
Robert McCarter 4
1
Children’s National Medical Center
and George Washington School
of Medicine and Health Sciences,
Washington, District of Columbia;
2
St Jude Children’s Research Hospital,
Memphis, Tennessee; 3Gundersen
Lutheran Medical Foundation, Inc.,
Madison, Wisconsin; 4Children’s
Research Institute, Washington,
District of Columbia; 5Florida
International University, Miami,
Florida

Purpose: To determine the safety of engaging HIV-positive (HIV+) adolescents in a Family
Centered Advance Care (FACE) planning intervention.
Patients and methods: We conducted a 2-armed, randomized controlled clinical trial in
2 hospital-based outpatient clinics from 2006–2008 with HIV+ adolescents and their surrogates (n = 76). Three 60–90 minutes sessions were conducted weekly. FACE intervention
groups received: Lyon FCACP Survey©, the Respecting Choices® interview, and completion
of The Five Wishes©. The Healthy Living Control (HLC) received: Developmental History,
Healthy Tips, Future Planning (vocational, school or vocational rehabilitation). Three-month
post-intervention outcomes were: completion of advance directive (Five Wishes©); psychological adjustment (Beck Depression, Anxiety Inventories); quality of life (PedsQL™); and HIV
symptoms (General Health Self-Assessment).
Results: Adolescents had a mean age, 16 years; 40% male; 92% African-American; 68% with
perinatally acquired HIV, 29% had AIDS diagnosis. FACE participants completed advance
directives more than controls, using time matched comparison (P  0.001). Neither anxiety,
nor depression, increased at clinically or statistically significant levels post-intervention. FACE
adolescents maintained quality of life. FACE families perceived their adolescents as worsening
in their school (P = 0.018) and emotional (P = 0.029) quality of life at 3 months, compared
with controls.
Conclusions: Participating in advance care planning did not unduly distress HIV+ adolescents.
Keywords: adolescents, advance care planning, communication, decision-making, family
intervention, HIV/AIDS
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Most youth with HIV are now expected to live past 21 years,1,2 yet mortality rates are
30 times higher than for the general US pediatric population.3 In 2006, in a perinatally infected cohort the mean age of death was 18 years.4 Overwhelming infection
due to immune system compromise contributes to morbidity.4 Thus, incorporating
advance care planning during the “antecedent period of decision making”5 may be
valuable in preparing for end-of-life (EOL) care. Quality advance care planning
includes discussing death, but differs from advance directives6 (ie, documenting
who you want to make health care decisions for you when you can’t make them for
yourself, the kind of medical treatment you want or do not want). Concern about
possible emotional distress has impeded families7,8 and providers from initiating
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conversations regarding EOL for teens living with a
life-threatening condition.9 Yet, talking about death and
dying and decision-making with such teens may benefit
them and their families.10–12 Teens want involvement in
their own EOL decisions. 13 Guidelines 11,14 recommend
conversations about advance care planning: 1) begin early
or at diagnosis of a life-threatening condition; 2) be shared
among the adolescent, family and health care provider;
and 3) be routine and structured. Goals for EOL care
frequently are unfulfilled, partially, because providers are
concerned that talking about death and dying can provoke
negative moods in the teen,15 as well as families.11,12 Our
goal was to develop/adapt a structured, safe intervention
that would provide an opportunity to talk about death
and dying while medically stable: planning for the worst,
hoping for the best.
Guided by a community-based participatory research
framework,16 the Family Centered Advance Care (FACE)
planning development and proximal outcomes are reported
elsewhere.17,18 This report presents the 3-month FACE postintervention outcomes: plans and actions, psychological
adjustment, and quality of life. The FACE intervention

is based on Leventhal’s theory of self-regulation19–21 and
Folkman and Lazarus’s theory of transactional stress and
coping22 (See Figure 1), postulating that interventions can
change the appraisal of an illness from a death threat to a
challenge with potential for growth and mastery.
We hypothesized that at 3 months, post-intervention
families in the FACE intervention study would be significantly more likely to: 1) complete an advance directive (AD);
2) maintain or have improved psychological adjustment;
3) maintain or have enhanced quality of life; and 4) maintain or
decrease HIV symptom severity, compared to families in the
Healthy Living Control (HLC) time-matched comparison.

Patients and methods
Participants
Between July 1, 2006 and May 31, 2008, 40 HIV-infected
adolescents and 40 adult surrogates (n = 80) were recruited
from the Children’s National Medical Center (CNMC) and
St. Jude Children’s Research Hospital (SJCRH) outpatient
adolescent HIV specialty clinics. Recruitment criteria for
adolescents included: aged 14–21 years, with an available
legal guardian (if under 18 years) or adult surrogate at least

FACE
Program
Protective
Process:
Spirituality
A or F

Major
Stressor
HIV/AIDS
Risk Process:
Psychological
Maladjustment
A or F

Outcomes
Plans and
Actions
A

Coping Efforts/
Strategies
A

Threat
Appraisal
A+F

Perceived Coping
Efficacy
A+F

Psychological
Adjustment
A, F

Quality of Life
A, F

Figure 1 Transactonal model of coping with stress.
Notes: Proximal program mediators are shown in shaded areas.
Plans and Actions = statement of treatment preferences and completion of Five Wishes© advance directive.
Psychological Adjustment = Symptoms of depressed or anxious mood as measured by the Beck Depression Inventory II or the Beck Anxiety Inventory.
Quality of Life = Total, School, Emotion, Physical and Social quality of life as measured by PedsQL™; HIV Specific Symptoms as measured by the General Health Assessment
for Children.
Abbreviations: A, adolescent; F, family; FACE, Family Centered Advance Care.
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21 years old who knew the adolescent’s HIV status, not in
foster care, no developmental delays, severe depression,
suicidal or homicidal ideation, dementia or psychosis.23–26
Additional family members were permitted to participate,
however, their data were excluded from analyses. The FACE
study was Institutional Review Board approved at both institutions. All participants provided written assent/consent.

Full details of the study methods are reported elsewhere.17,18
In brief, three 60–90 minute semi-structured family interview
sessions were conducted by a trained/certified interviewer at
weekly intervals: Session 1: Lyon Advance Care Planning
Survey© – Adolescent and Surrogate Versions: Session 2:
The Respecting Choices Interview® Session 3: Completion
of The Five Wishes.©
HLC subjects were also administered in three weekly
60–90 minute sessions and family format to control for
time, attention and/or related Hawthorn effects. Session 1:
Developmental History.27 Session 2: Safety Tips.28 Session 3:
School and Career Planning interview.29

depression over the past two weeks on a 4-point Likert scale
for adolescents 13 years of age.
The Pediatric Quality of Life Inventory™ 4.033–35 is a
23-item modular measure of health-related quality of life in
children and adolescents. Four dimensions of functional quality of life (physical, emotional, social, school) are assessed.
It has the strongest norms, validity, and reliability of the
measures available. Norms exist for up to age 18.9 years,
which was extended upward to allow for one assessment
measure across participants.
General Health Assessment for Children36 is a selfreport measure for adolescents aged 12–20 years. The HIVrelated symptom subscale was used to assess the degree
of distress caused by HIV-related physical symptoms. It is
comprised of 18 items rated on a six-point Likert scale (“Not
at All” to “Extremely”).
Measures were administered separately to both the adolescent and surrogate, at baseline and at the 3-month postintervention follow-up.
Stage of Illness was measured by the CDC (Centers for
Disease Control and Prevention) classification system in
place at the time of the study.37

Outcome measures

Study design/data collection

Five Wishes (Towey and Aging with Dignity) is a legal
document that facilitates expression of treatment preferences,
if they were unable to communicate their wishes and includes
the selection of a surrogate decision-maker. It can also serve
as a tool to facilitate the participation of adolescents under
age 18,30 but must be signed by their parent/legal guardian
to be legally sufficient.
Statement of Treatment Preferences31 expresses values and goals related to future decision making regarding
frequently occurring scenarios common to individuals with
complications of AIDS.32 It was used to document specific
treatment preferences of patients and their surrogates’
understanding of what the patient would want. Patients and
surrogates chose one of three options, “to continue all treatment and keep fighting,” “to stop all treatment to prolong my
life,” and “don’t know.”
Beck Anxiety Index (BAI)24 is a 21-item measure of
anxiety rated on a 4-point Likert scale of symptoms over the
past week. The BAI has demonstrated adequate reliability
and validity to clinically assess anxiety in individuals aged
17 to 80. We extended downward to age 14 to allow for consistency of data collected by a single measure of anxiety.
Beck Depression Inventory-II25 is a 21-item scale
self-report measure to assess presence of symptoms of

Adolescent/surrogate dyads were randomly assigned to
one of two study groups, FACE versus HLC. Randomization utilized permuted block design, based on study site, to
ensure the same numbers would be recruited to FACE and
HLC. All participants were given a brochure with information on advance care planning and received standard of care.
Follow-up data were collected face-to-face at 3-months postintervention with two exceptions. A research assistant, not
the facilitator, administered follow-up questionnaires orally
to control for literacy. Progress of participants through the
trial is illustrated in Figure 2.

FACE intervention and healthy living
control (HLC)

©
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Statistical analysis
To assess whether the FACE intervention participants established an advance directive, medical charts were reviewed
for documented completion.
Before we implemented parametric analyses, we evaluated the normality and variance homogeneity assumptions
and when necessary implemented data transformations to
ensure the data met these assumptions. Following analyses
involving data transformations, the results were back transformed to return the estimates to their original scale and
units. In this event, adjusted means are reported which also
control for baseline levels of scores.
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Assessed for
eligibility
(n = 86, 43 dyads)
Excluded (n = 4, 2 dyads)
Not meeting inclusion criteria (n = 2)
1 = homicidal mother
1 = suicidal mother
1 = Aunt withdrew after baseline

Enrollment

Randomized (n = 80, 40 dyads)

Allocation

Follow up

Allocated to FACE intervention (n = 21
dyads)
Received allocated Intervention (n = 18)
Did not receive allocated intervention
n = 1 dyad assigned to intervention
received HLC)*

Allocated to HLC comparison (n = 19
dyads)
Received allocated intervention (n = 17)
Did not receive allocated intervention
(n = 1 dyad assigned to HLC
received FACE)*

Lost to follow up (n = 0)
Discontinued FACE intervention (n = 0)

Lost to follow up (n = 0)
Discontinued HLC intervention (n = 0)

Analyzed (n = 20 dyads)
Excluded from analysis (n = 1 dyad)**

Analyzed (n = 18 dyads)
Excluded from analysis (n = 1 dyad)***

Analysis

Figure 2 Flow of participants through each stage of the trial.
Notes: *Kept in analysis, per intent-to-treat design, as if received allocated condition; **n = 1 randomized intervention adolescent became psychotic & ineligible before Session 1;
***n = 1 randomized adolescent control was shot & withdrew from study before Session 1.

To evaluate changes in psychological adjustment and
quality of life, ANCOVA (analysis of covariance) was used
to estimate and compare group means, with 95% confidence
intervals, by study group and assess the effect of the two groups.
Each estimate was derived controlling for baseline anxiety and
depression scores, as well as any covariates found in preliminary analyses to differ between groups. The slope coefficient for
group was used to estimate the magnitude of any differences.
A t-test was employed to assess statistical significance.
In secondary analyses, logistic regression models were
used to test for a trend in the outcome based on the level of
severity of illness using CDC criteria.37 It was unnecessary to
code for intervention exposure, because all subjects attended
100% of Sessions 1–3. Estimates were derived separately for
surrogate and adolescent. However, when possible, overall
estimates were derived by treating the dyad as a cluster, again
controlling for baseline levels, as well as any covariates found
in preliminary analyses to differ between groups.
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Results
Sample characteristics
Randomization produced an acceptable balance respecting
group assignment by sample characteristics at baseline.17
Of eligible families, 97% chose to participate. As planned,
40 dyads were randomized. However, two dyads were excluded
from analyses due to withdrawal from the study prior to the
start of Session 1. See Figure 2. Data analyses were based on
38 dyads, using an intent-to-treat design, which included the 2
misallocated dyads. The characteristics of these 38 adolescents
are presented in Table 1. There were no adverse events.

Plans and actions
FACE adolescents completed the Five Wishes© with their
families at a higher rate than the HLC adolescents (90%
versus 11%, P  0.001; Table 2). At Baseline, one adolescent in the FACE group previously completed an AD and 5
were unsure whether they had. At 3-month post-intervention
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Table 1 3-month post-intervention characteristics for family centered (FACE) and healthy living control (HLC) adolescents with HIV/
AIDS (n = 38)
Adolescent

FACE intervention

HLC group

characteristics

n = 20

n = 18

16.65 (±2.11)

16.58 (±2.38)

Males

8 (40%)

7 (39%)

Females

12 (60%)

11 (61%)

17 (94%)

18 (90%)

1 (6%)

2 (10%)

Perinatal infection

15 (75%)

11 (61%)

Behavioral infection

5 (25%)

7 (39%)

A 1–3 (asymptomatic)

5 (25%)

11 (61%)

B 1–3 (symptomatic)

6 (30%)

5 (28%)

C 2–3 (AIDS)

9 (45%)

2 (11%)

Age (in years)
Mean (±SD)
Gender

Race/Ethnicity
Black/African American
 Non-African American
Mode of HIV Transmission

CDC classification

1

2

Education
 No High School Diploma/in HS

12 (60%)

10 (56%)

HS or GED equivalent

4 (20%)

6 (33%)

Some college/no bachelors

4 (20%)

2 (11%)

 Federal poverty line

7 (35%)

6 (33%)

100%–200% of Federal poverty line

1 (5%)

3 (17%)

201%–300% of Federal poverty line

4 (20%)

4 (22%)

300% of Federal poverty line

6 (30%)

3 (17%)

Unknown

2 (10%)

2 (11%)

Permanently housed

18 (90%)

17 (94%)

Unstable living arrangement

2 (10%)

1 (6%)

Heterosexual

17 (85%)

15 (83%)

Homosexual

1 (5%)

1 (5.6%)

Bisexual

2 (10%)

1 (5.6%)

Don’t know

0 (0%)

1 (5%)

19 (95%)

17 (94%)

1 (5%)

1 (6%)

Mean (SD)

102.32 (±64.14)

80.27 (±66.16)

Range

11–220

3–207

Mean (SD)

9.42 (±5.35)

11.5 (±5.21)

Range

0–18

0–18

Income

Housing status

Sexual orientation

Marital status
Single
Married/Living
Together
Length of time known diagnosis (in months)

Age learned HIV+ (in years)

Notes: Data are from the old Centers for Disease Control and Prevention Classification system.
b
No patient had category C1.
Abbreviations: CDC, Centers for Disease Control and Prevention; (1992); GED, general educational development; FACE, Family Centered Advance Care planning intervention; HLC, healthy living control for time and attention, matched comparison group; SD, standard deviation.
a
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uncertainty was resolved. Five Wishes© completion did not
significantly differ by gender, race, ethnicity, education,
employment status, CDC stage of illness, number of guardians present, length of time with known diagnosis or age at
diagnosis. However, teens whose surrogates were not biological family members (n = 8/10; 80%) were more likely to
complete the Five Wishes© than those whose surrogates who
were biological relatives (11/28; 40%, P = 0.031).

Decision to stop extraordinary
treatment
On the Statement of Treatment Preferences the majority of
adolescents chose to continue all treatments, regardless of
quality of life. Ten percent of adolescents in Situation 1, 26%
in Situation 2, and 24% in Situation 3 chose to discontinue
extraordinary treatment. FACE adolescents appeared to be no
more likely than HLC adolescents to discontinue treatment
across the three situations, but the absence of statistical significance in this small sample is not absence of an effect. See
Table 2. Non-African-American adolescents were significantly
more likely to choose discontinue treatment (P = 0.026). A trend
emerged for non-African-American adolescents to be more
likely to discontinue treatment under Situation 2 (P = 0.060),
if they were to become physically disabled and require nursing
home care. No associations reached significance between the
three Situations by gender, education, employment status, age,
length of time known diagnosis or age learned HIV status.

Psychological adjustment
FACE adolescents who talked about their own prospective
death and dying with their families in facilitated conversations by a trained facilitator were no more depressed or
anxious than HLC adolescents at 3-months post-intervention
(Table 3). Surrogates in the FACE group demonstrated slight
increases in depressed and anxious mood compared to controls at 3-months post-intervention, controlling for baseline
levels. However, increases were not clinically or statistically significant, but in minimal ranges and could be due to
chance. Baseline levels of depression and anxiety predicted
depression (adolescents, P = 0.002; surrogates, P  0.001)
and anxiety (adolescents, P = 0.003; surrogates P  0.001)
at 3-months post-intervention. Overall, adjusted mean levels
of adolescent and surrogate depression and anxiety (Table 3)
at 3-month post-intervention fell in the minimal clinical
range. Depression and anxiety at 3-month post-intervention, controlling for baseline, did not differ significantly by
gender, race, ethnicity, education, employment status, age at
diagnosis, length of time with known diagnosis, family type
or number of guardians present. Adolescents assigned to the
intervention had statistically significantly higher depressed
mood compared to controls at baseline, although mood levels
were clinically insignificant in the minimal range.

Quality of life
Quality of life as measured by the PedsQL™ Total score was
maintained for adolescents in both FACE and HLC and there

Table 2 3-month post-intervention outcomes: plans and actions
Outcomes

Completed Five Wishes or other AD

FACE

HLC

FACE intervention

HLC comparison

n = 20

n = 18

19a (95%)

P+ value

2 (11%)

0.001*

Statement of Treatment Preferences:

Stop all efforts

Situation #1

3 (15%)

1 (6%)

0.187a

Situation #2

5 (25%)

5 (28%)

1.000a

Situation #3

6 (30%)

3 (17%)

0.528a

+

Notes: +“To stop all efforts to keep me alive (For me quality of life is more important than length of life). This includes such treatments as CPR, blood transfusions, kidney
dialysis and tube feedings.
1. If I have serious complications from AIDS, such as an overwhelming infection or pneumonia, so that I was facing a long hospital stay, with many medical treatments AND
my chance of living through this complication is low (for example, only 5 out of 100 kids will live), I would choose the following: (Whatever my choice, I want to be kept as
comfortable as possible).
2. If I have AIDS and a serious complication, such as an overwhelming infection or pneumonia and have a good chance of living through this complication, but it was expected
that I would never be able to walk or talk again, and I would need 24 hour nursing care, I would choose the following. (Whatever my choice, I want to be kept as comfortable
as possible).
3. If I have AIDS and a serious complication, such as an overwhelming infection or pneumonia and have a good chance of living, but it was expected that I would never know
who I was or who I was with and would need 24 hour nursing care, I would choose the following. (Whatever my choice, I want to be kept as comfortable as possible).
Notes: aData are frequencies. 1-sided Fisher Exact Test. 1 patient completed Five Wishes outside of one month post session window for protocol. No significant differences
by perinatal vs behavioral transmission for completing advance directive, P = 0.284.
*Significant at the P = 0.05 level.
Abbreviations: CPR, cardiopulmonary resusication; FACE, Family Centered Advance Care Planning; EOL, end-of-life; HIV/AIDS, human immunodeficiency virus/acquired
immune deficiency syndrome; HLC, healthy living control.
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Table 3 3-month post-intervention outcomes: psychological adjustment by treatment group controlling for baseline levels
Outcomes

FACE (n = 40)

HLC (n = 36)

Intervention

Comparison

P+ value

BAI adjusted mean scores with upper and lower 95% confidence intervals (Range 0–63; 0 to 7 = minimal anxiety)
Adolescent
Baseline

2.76 (1.38–4.60)

1.38 (0.44–2.84)

0.170

3 month post-intervention

2.48 (1.14–4.34)

1.06 (0.24–2.45)

0.149

Baseline

1.64 (0.62–3.14)

2.51 (1.14–4.41)

0.395

3 month post-intervention

2.48 (1.20–4.22)

2.35 (1.06–4.15)

0.901

Surrogate’s own mood

BDI-II adjusted mean scores** with upper and lower 95% confidence intervals (range 0–63; 0–13 = minimal depressed mood)
Adolescent
Baseline

7.8 (4.73–11.69)

1.27 (0.22–3.17)

0.001*

3 month post-intervention

5.06 (2.57–8.39)

3.43 (1.35–6.45)

0.432

Baseline

2.0 (0.66–4.09)

3.65 (1.62–6.50)

0.261

3 month post-intervention

2.73 (1.26–4.77)

3.29 (1.57–5.65)

0.676

Surrogate’s own mood

Abbreviations: BAI, Beck Anxiety Inventory; BDI-II, Beck Depression Inventory; 2nd Edition. Higher scores represent higher symptom levels. FACE, Family
Centered Advance Care planning; HLC, healthy living control.

were not significant differences by group or on any of the
subscales (Table 4).
However, surrogates’ perception of their adolescents’
Total quality of life was significantly lower for surrogates in
the FACE versus HLC group (P = 0.032) at 3-months, controlling for baseline levels. FACE surrogates rated their adolescents as having poorer school quality of life at 3-months
post-intervention (66.9 versus 80.0, P = 0.011) and poorer
emotion quality of life (74.8 versus 85.7, P = 0.029), compared to HLC surrogates. The physical and social subscale
scores were not significantly different by group, controlling
for baseline levels.

Category B (symptomatic, not AIDS) had lower physical
scores (more symptoms) than those in Category A (asymptomatic) or C (AIDS) (P = 0.005) and they scored higher on
Total Symptoms (P = 0.015).
Table 4 3-month post-intervention outcome: quality of life:
PedsQL™ adjusted mean scores with 95% confidence intervals
(ci upper and lower limits), controlling for baseline levels
Outcomes

FACE

HLC

Intervention

Comparison

n = 40

n = 36

Adjusted Mean/CI

Adjusted Mean/CI

TOTAL

338.5 (321–355)

345.6 (327.3–363.1)

0.568

Physical

93.1 (89.4–96.6)

93.8 (91.3–96.3)

0.692

School

75.0 (68.4–82.0)

77.7 (70.7–85.2)

0.589

 Emotional

82.0 (74.8–88.6)

82.5 (74.4–90.0)

0.921

90.3 (86.5–93.9)

92.0 (88.6–95.2)

0.297

P+ value

Adolescent

Quality of life – HIV specific symptoms
On the GHAC trends towards more HIV-specific symptoms
emerged in FACE vs HLC adolescents for the following
symptoms (See Table 5): rash or itching; fatigue or weakness;
and trouble sleeping. However, the scores reflect very low
levels of symptoms, if examined using the midpoint cut-off
for reporting symptoms which distressed them, moderately,
very much or extremely. There were no statistically significant
differences between FACE and HLC teens for any other HIV
related symptoms 3-months post-intervention. There also was
no relationship between Treatment Preferences and symptom
score (P = 0.39).
In secondary analysis using a regression model examining
all adolescents regardless of treatment arm, those in CDC

HIV/AIDS - Research and Palliative Care 2010:2

Social

Surrogate perception of adolescent quality of Life
TOTAL

324.8 (308.4–340.4)

349.3 (333.4–364.6)

0.032*

Physical

92.3 (89.3–95.1)

93.0 (89.7–96.1)

0.692

School

66.9 (60.0–74.1)

80.0 (72.1–88.3)

0.018*

 Emotion

74.8 (67.2–81.6)

85.7 (78.9–92.0)

0.029*

Social

91.0 (88.0–93.8)

92.7 (89.2–95.9)

0.297

Notes: *Significant at P = 0.05. +All P values control for baseline using a t-test to
assess significance. Range of subscale scores is 0 to100. Higher scores represent
better quality of life.
Abbreviations: FACE, Family Centered Advance Care planning; HLC, healthy living
control.
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Table 5 3-month post-intervention outcomes: quality of life-HIV specific symptoms: general health assessment for children HIV symptoms.
Percentage of adolescents reporting moderately, very much or extremely distressed by symptom at 3-month post-intervention controlling for baseline levels of symptoms
HIV specific symptoms

FACE intervention

HLC comparison

n = 20

n = 18

P value

Physical/bodily pain

5%

0%

0.210

Coughing/Wheezing

10%

0%

0.604

Nausea/vomiting

5%

0%

0.737

Skin problems (rash, itching, etc)

5%

0%

0.063+

Fatigue

0%

5%

0.095+

Feeling dizzy/lightheaded

5%

0%

0.178

Fever/night sweats/shaking/chills

5%

0%

0.737

Loss of appetite

5%

0%

0.663

Trouble sleeping

0%

0%

0.058+

Eye trouble/problems with vision

0%

5%

0.734

Headaches

5%

0%

0.342

Dry or painful mouth/trouble swallowing

0%

0%

1.0

Chest pain or tightness

5%

0%

1.0

Difficulty breathing or catching breath

0%

0%

0.656

Runny nose/sinus trouble

10%

0%

0.479

Muscle aches/joint or bone pain

0%

0%

0.232

Pain, numbness or tingling

0%

0%

0.792

Overall discomfort

0%

0%

0.697

Notes: +All P values control for baseline using a t-test to assess significance at the 0.05 level.
Abbreviations: FACE, Family Centered Advance Care planning; EOL, end-of-life; HIV/AIDS, human immunodeficiency virus/acquired immune deficiency syndrome; HLC,
healthy living control.

Discussion
Using a rigorous randomized 2-arm design and intent-to-treat
analysis, the FACE intervention demonstrated that advance
care planning can be safely administered to HIV+ teens,
ie, did not cause significant emotional distress or adverse
events. FACE prepared surrogate decision makers for their
role in EOL discussions and treatment decisions.
Our study challenges earlier findings38–47 with 100% of
our primarily African-American FACE group completing an
advance directive. The fact that several families spontaneously requested an extra copy of the Five Wishes© to complete for themselves suggests this outcome was not a result
of the Hawthorne Effect (desire to please the researcher).
Our results are consistent with a report by Washington, who
in a study of African-American primary caregivers who
made decisions about EOL care, found strong support for
hospice care.48
Participating in the FACE intervention did not influence decisions to discontinue treatment. Our goal was to
safely assist adolescents with HIV/AIDS to make decisions
with their families about their EOL preferences, while
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still cognitively intact.49–51 People sometimes change their
AD as the disease progresses, for example, deciding to
“Allow a Natural Death,” rather than to continue aggressive
treatment(s). Thus, EOL care decision making is best understood as an ongoing process, rather than a one-time event,
and should be revisited.52–57
Consistent with earlier adult studies44,45,58–61 AfricanAmerican adolescents in our cohort preferred to continue
all treatments at EOL at rates significantly higher than
non-African-American adolescents, however, because of
our small sample size this result may not be stable. This
finding differs from that of Hinds and colleagues62 who
reported race did not influence DNR (do not resuscitate)
status in a pediatric oncology sample. This difference
could be due to the timing of decision making, which in
the Hinds study was during what Hansen5 calls the “central
period” of decision making (where EOL is eminent), rather
than the “antecedent period” as was done in our study.
Our African-American families were willing to think and
talk about EOL issues and were prepared for their role as
decision-makers.17,18
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FACE achieved rates of recruitment in excess of those
reported in adults in which only 30%–47% of eligible
patients participated in EOL studies.63–66 Nevertheless, 54%
of potential participants approached prior to screening for
eligibility, declined to participate. Dyadic/family studies pose
a challenge as sometimes the patient wants to participate, but
the family member does not have time, wants to protect the
patient, or is uninterested.67
Several factors may explain the success of the FACE
intervention. First, we integrated processes identified with
successful HIV interventions,68–70 specifically, communitybased participation in development and adaptation to ensure
cultural sensitivity and to reduce health disparities.16,17,71,72
Second, we used a competency-based program to ensure
consistency in the delivery of the intervention as measured
by two components: 1) facilitator certification and 2) patient
and family ratings of quality of communication, consistent
with the recommendations of Dickens.72 Third, the high rate
of retention suggests participants were highly motivated to
seek education and improve long-term care. Fourth, FACE
was highly family-centered. Finally, research assistants were
hired and retained only if they committed to flexibility in
scheduling sessions and if successfully certified (Respecting
Choices® interview).
In contrast to Bakitas and colleagues,63 we did not find
improvements in quality of life or mood for the intervention
group, rather healthy levels of mood and quality of life were
maintained. Floor effects for mood and ceiling effects for
quality of life limited the power to detect differences, and
differences that we found were within healthy ranges and
therefore not clinically significant. The reason(s) higher
levels of depressed mood were found at baseline for adolescents randomly assigned to FACE versus HLC are unclear.
Baseline assessment occurred before randomization, so
assignment to the intervention group did not impact mood.
Unexpectedly, FACE surrogates perceived their adolescents’ school and emotional quality of life was lower
compared to HLC surrogates. This may reflect increased
knowledge of school related and emotional problems for
their teens that emerged during the facilitated conversation.
Also, FACE surrogates reported more sadness and anxiety
at 3-month post-intervention, than FACE adolescents who
reported less compared to baseline levels. Although the
changes were not clinically or statistically significant, they
suggest that adolescents may have found talking about their
own death and dying less anxiety provoking and sad than
their families did. This finding needs further study.
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Conclusion
The FACE results begin to fill the gap on ethnocultural factors
that influence EOL decision making and preferences among
HIV-positive adolescents, who demonstrated a willingness
to discuss difficult and emotionally-laden issues with their
surrogate decision makers and complete advance directives,
potentially “breaking the ice” for future EOL conversations.
Going beyond measuring the effect of communication on
satisfaction, we studied outcomes related to advance care
planning, quality of life and mood using standardized
measures. The FACE results suggest that research into this
sensitive area is safe. Probable benefits at the time of dying
for teens and families, or after death for families, remain to
be demonstrated in future studies.

Funding/support
The study was funded by grant 5R34MH072541-03 from
the National Institute of Mental Health. The content is
solely the responsibility of the authors and does not necessarily represent the official views of the National Institute
of Mental Health or the National Institutes of Health. This
trial has been registered at www.clinicaltrials.gov Identifier
#NCT00723476.

Acknowledgments
We wish to thank our families for their participation and
the community for their help in developing this protocol,
especially Ebony Johnson. We also thank Connie Trexler
and Keith Selden who facilitated the community advisory boards and focus groups. We extend our gratitude
to our research assistants who worked with our families:
Stephanie Lee, Portia Pieterse, Yolanda Peele, Ellin Kao,
LaQuisha Mark, Mackenzie Nowell, Megan Banet, Megan
L Wilkins, Ericka Midgett, J Christopher Young, Elizabeth
Kolivas. We thank Jennifer Marsh and Saeid Goudarzi for
help with statistical support and data management early in
the study. We thank our consultants Drs Beatrice Krauss,
Mary Ann McCabe, Bruce Rapkin and Robert Washington
who helped during the developmental phase of the study
and Dr Tomas Silber for his ethics consultations. We thank
the health care providers and case managers who referred
families to our study, especially Drs Hans Spiegel and
Natella Rakhmanina.

Disclosures
Linda Briggs, receives royalties from the Respecting
Choices® interview. However, the remaining authors have no

submit your manuscript | www.dovepress.com

Dovepress

35

Dovepress

Lyon et al

financial relationships or other conflicts of interest relevant
to this article to disclose.

References

1. Justice AC, McGinnis KA, Skanderson M, et al. Towards a combined
prognostic index for survival in HIV infection: the role of ‘no-HIV’
biomarkers. HIV Med. 2009;11(2):143–151.
2. McConnell MS, Byers RH, Frederick T, et al. Trends in antiretroviral
therapy use and survival rates for a large cohort of HIV-infected children
and adolescents in the United States, 1989–2001. Epidemiology and
Social Science. 2005;38(4):488–494.
3. America’s Children in Brief: Key National Indicators of Well-Being:
2008. Available at: http://www.childstats.gov/americaschildren.
4. Brady MT, Oleske JM, Williams PL, et al. Declines in mortality and
changes in causes of death in HIV-1 infected children during the HAART
era. J Acquir Immune Defic Syndr. 2010;(5391):86–94.
5. Hansen L, Archbold PG, Stewart BJ. Role strain and ease in decisionmaking to withdraw or withhold life support for elderly relatives. J Nurs
Scholarsh. 2004;36(3):233–238.
6. Grady PA. Introduction: Papers from the National Institutes of Health
State-of-the-Science Conference on improving end-of-life care. J Palliative Med. 2005;8(Suppl 1):S1–S3.
7. Bearison D. They Never Want to Tell You. Cambridge, MA: Harvard
Univ Press; 1991.
8. Bluebond-Langner M. Private Worlds of Dying Children. Princeton,
NJ: Princeton University Press; 1978.
9. Hinds PS, Burghen EA, Pritchard M. Conducting end-of-life studies in
pediatric oncology. West J Nurs Res. 2007;29:448–465.
10. Hinds PS, Schum L, Baker JN, Wolfe J. Key factors affecting dying
children and their families. J Palliat Med. 2006;8:S70–S78.
11. Field MJ, Behrman RE, editors: When Children Die: Improving palliative and end-of-life care for children and their families. Washington,
DC: Institute of Medicine, National Academy Press; 2002.
12. Walsh-Kelly CM, Lang KR, Chevako J, et al. Advance directives in a
pediatric emergency department. Pediatrics. 1999;103:826–830.
13. Lyon ME, McCabe MA, Patel K, D’Angelo LJ. What do adolescents
want? An exploratory study regarding end-of-life decision-making.
J Adolesc Health. 2004;35(6):529 e1–e6.
14. American Academy of Pediatrics: Committee on Bioethics and
Committee on Hospital Care. Palliative care for children. Pediatrics.
2000;106:351–357.
15. Kane JR. Pediatric palliative care moving forward: Empathy, competence, quality, and the need for systematic change. J Palliat Med.
2006;9:847–849.
16. Bogart LM, Uyeda K. Community-based participatory research:
Partnering with communities for effective and sustainable behavioral
health interventions. Health Psychol. 2009;28(4):391–393.
17. Lyon ME, Garvie PA, Briggs L, He J, D’Angelo L, McCarter R. Development, feasibility and acceptability of the Family-Centered (FACE)
Advance Care planning intervention for adolescents with HIV. J Palliat
Med. 2009;12(4):363–372.
18. Lyon ME, Garvie PA, McCarter R, Briggs L, He J, D’Angelo L.
Who will speak for me? Improving end-of-life decision-making for
adolescents with HIV and their families. Pediatrics. 2009;123(2):
e199–e206.
19. Leventhal HH, Nerenz DR, Steele DJ. Illness representations and coping
with health threats. In: Baum A, Taylor SE, Singer JE, editors: Handbook
of Psychology and Health, Vol. IV: Social psychological aspects of health,
A. New Jersey: Laurence Erlbaum Associates, Inc; 1984. p. 219–252.
20. Leventhal H, Diefenbach M. The active side of illness cognition. In:
Skelton JA, Croyle RT, editors Mental Representation in Health and
Illness. New York, NY: Springer Verlag; 1991:247–272.
21. Leventhal H, Benyamini Y, Shafer C; Lay beliefs about health and
illness. In: Ayers S, editors: Cambridge Handbook of Psychology,
Health and Medicine. Cambridge, MA: Cambridge University Press;
2007:124–128.

36

submit your manuscript | www.dovepress.com

Dovepress

22. Lazarus RS, Folkman S. Appraisal, and Coping. New York, NY: Springer
Publishing Company; 1984.
23. Power C, Selnes OA, Grim JA, McArthur JC. HIV Dementia Scale:
a rapid screening test. J Acquir Immune Defic Syndr Hum Retrovirol.
1995;8:273–278.
24. Beck AT, Steer RA. Beck Anxiety Inventory Manual. San Antonio, TX:
The Psychological Corporation, Harcourt Brace & Company; 1993.
25. Beck AT, Steer RA, Brown GK. Beck Depression Inventory Manual
(2nd edition). San Antonio, TX: The Psychological Corporation,
Harcourt Brace & Company; 1996.
26. King CA, Katz SH, Ghaziuddin N, Brand E, Hill E, McGovern L.
Diagnosis and assessment of depression and suicidality using the NIMH
Diagnostic Interview Scale for Children-DISC-2.3-National Institute
of Mental Health. J Abnormal Child Psych. 1997;25(3):173–181.
27. Barkley RA. Attention-Deficit Hyperactivity Disorder: A clinical
workbook. New York, NY. The Guilford Press; 1993.
28. American Academy of Pediatrics: Bright Futures. 2005. Accessed
January 10, 2010. Available from: http://brightfutures.aap.org/web/
healthCareProfessionalstoolsAndResources.asp.
29. Wolf-Branigin M, Schuyler V, White P. Improving quality of life
and career attitudes of youth with disabilities: Experiences from
the Adolescent Employment Readiness Center. Res Soc Work Prac.
2007;17:324–334.
30. Wiener L, Ballard E, Brennan T, Battles H, Martinez P, Pao M.
How I wish to be remembered: the use of an advance care planning
document in adolescent and young adult populations. J Palliat Med.
2008;11:1309–1313.
31. Hammes BJ, Briggs L. Respecting choices: advance care planning
facilitator manual. Includes Statement of Treatment Preferences. La
Crosse, WI: Gundersen Lutheran Medical Foundation; 2000.
32. Watcher RM, Lo B. Advance directives for patients with Human
Immunodeficiency Virus infection. Crit Care Clin. 1993;9:125–135.
33. Varni JW, Seid M, Rode CA. The PEDSQL: measurement model for
the pediatric quality of life inventory. Med Care. 1999;37:126–139.
34. Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of
the Pediatric Quality of Life Inventory version 4.0 generic core scales
in healthy and patient populations. Med Care. 2001;39:800–812.
35. Varni JW, Burwinkle TM, Seid M, Skarr D. The PedsQLTM 4.0 as a
pediatric population health measure: Feasibility, reliability, and validity.
Ambul Pediatr. 2003;3:329–341.
36. Gortmaker SL, Lenderking WR, Clark C, et al. Development and Use
of a Pediatric Quality of Life Questionnaire in AIDS Clinical Trials:
Reliability and Validity of the General Health Assessment for Children.
In: Drotar D, editors, Measuring Health-Related Quality of Life in
Children and Adolescents: Implications for Research and Practice.
Mahway, NJ: Lawrence Erlbaum Associates; 1998:219–235.
37. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR: Recomm Rep.
1992;41:1–17.
38. Morrison RS, Zayas LH, Mulvihill M, Baskin SA, Meier DE. Barriers to
completion of health care proxies: An examination of ethnic differences.
Arch Intern Med. 1998;158:2493–2497.
39. Blackhall LJ, Frank G, Murphy ST, Michel V, Palmer JM, Azen SP.
Ethnicity and attitudes towards life sustaining technology. Soc Sci Med.
1999;48:1779–1789.
40. Kiely DK, Mitchell SL, Marlow A, Murphy KM, Morris JN. Racial
and state differences in the designation of advance directives in nursing
home residents. J Am Geriatr Soc. 2001;49:1346–1352.
41. Degenholtz HB, Arnold RA, Meisel A, Lave JR. Persistence of racial
disparities in advance care plan documents among nursing home
residents. J Am Geriatr Soc. 2002;50:378–381.
42. Degenholtz HB, Thomas SB, Miller MJ. Race and the intensive care
unit: Disparities in preferences for end-of-life care. Crit Care Med.
2003;31(5 Suppl):S373–S378.
43. Smith DB. Health Care Divided: Race and Healing a Nation. Ann
Arbor, MI: The University of Michigan Press; 2002:24–27.

HIV/AIDS - Research and Palliative Care 2010:2

Dovepress
44. Phillips RS, Hamel MB, Teno JM, et al. Patient race and decisions
to withhold or withdraw life-sustaining treatments for seriously ill
hospitalized adults. SUPPORT Investigators. Study to Understand
Prognoses and Preferences for Outcomes and Risks of Treatment. Am
J Med. 2000;108:14–19.
45. Krakauer EL, Crenner C, Fox K. Barriers to optimum end-of-life care
for minority patients. J AM Geriatr Soc. 2002;50(1):182–190.
46. Crawley LM. Racial, cultural and ethnic factors influencing end-of-life
care. J Palliative Med. 2005;8:S58–S69.
47. Lyon ME, Williams PL, Woods ER, et al. Do not resuscitate
orders and/or hospice care, psychological health and quality of life
among children/adolescents with AIDS. J Palliative Med. 2008;11:
459–469.
48. Washington R. Press Release: Study by former DC Commissioner of
mental health finds hospice care benefits black families. Montgomery
Hospice June 24, 2004. Accessed January 10, 2010. Available from:
http://www.montgomeryhospice.org/pdfs/20040610.pdf. [June 24,
2004].
49. Allison S, Wolters PL, Brouwers P. Youth with HIV/AIDS: Neurobehavioral consequences. In: Paul RH, Sachtor NC, Valcour V, Tashima KT,
editors. HIV and the Brain, Totowa, NJ: Current Clinical Neurology,
Humana Press; 2009:187–211.
50. Lyon ME, McCarter R, D’Angelo L. Detecting HIV associated neurocognitive disorders in adolescents: what is the best screening tool?
J Adolesc Health. 2009;44(2):133–135.
51. Wood SM, Shah SS, Steenhoff AP, Rutstein RM. The impact of
AIDS diagnoses on long-term neurocognitive and psychiatric outcomes of surviving adolescents with perinatally acquired HIV. AIDS.
2009;23(14):1859–1865.
52. Lautrette A, Darmon M, Megarbane B, et al. A communication strategy
and brochure for relatives of dying patients in the ICU. N Engl J Med.
2007;356(5):469–478.
53. Lilly CM, DeMeo DL, Sonna LA, et al. An intensive communication
intervention for the critically ill. Am J Med. 2000;109(6):469–475.
54. Lilly CM, Sonna LA, Haley KJ, Massaro AF. Intensive communication: four-year follow-up from a clinical practice study. Crit Care Med.
2003;31(5):S394–S399.
55. Romer AL, Hammes BJ. Comunication, trust, and making choices:
advance care planning four years on. J Palliat Med. 2004;7:35–40.
56. Tulsky JA. Beyond advance directives: importance of communication
skills at the end of life. JAMA. 2005;294(3):395–365.
57. Tulsky JA. Interventions to enhance communication among patients,
providers, and families. J Palliat Med. 2005;8:S95–S102.
58. AARP. AARP North Carolina End of Life Care Survey: African
American Members. Report prepared by Rachelle Cummins, MA.
2003. Accessed on January 10, 2010. Available from: http://research.
aarp.org/.

Talking to teens about death and dying
59. Haas JS, Weissman JS, Cleary PD, et al. Discussion of preferences
for life-sustaining care by persons with AIDS. Arch Intern Med.
1993;153:1241–1248.
60. Emanuel EJ, Fairclough DL, Emanuel L. Attitudes and desires related to
euthanasia and physician-assisted suicide among terminally ill patients
and their caregivers. JAMA. 2000;284:2460–2468.
61. Thompson BL, Lawson D, Croughan-Minihane M, Cooke M. Do
patients’ ethnic and social factors influence the use of do-not-resuscitate
orders? Ethn Dis. 1999;9:132–139.
62. Baker JN, Rai S, Lui W, et al. Race does not influence Do-Not-Resuscitate
Status or the number or timing of End-of-Life discussions at a pediatric
oncology referral center. J Palliat Med. 2009;12(1):71–76.
63. Bakitas M, Lyons KD, Hegel MT, et al. Effects of a palliative care
intervention on clinical outcomes in patients with advanced cancer:
the Project ENABLE II randomized controlled trial. JAMA. 2009;302:
746–749.
64. Davies B, Reimer JC, Brown P, Martens N. Challenges of conducting
research in palliative care. Omega (Westport). 1995;31:263–273.
65. Hudson P, Aranda S. McMurray N. Randomized controlled trials in
palliative care: overcoming the obstacles. Int J Palliat Nurs. 2001;7:
427–434.
66. McMillan SC, Weitzner MA. Methodologic issues in collecting data
from debilitated patients with cancer near the end of life. Oncol Nurs
Forum. 2003;30:123–126.
67. Kirchhoff KT, Kehl KA. Recruiting participants in end-of-life research.
Am J Hosp Palliat Care. 2008;24:515–521.
68. Ingram BL, Flannery D, Elkavich A, Rotheram-Borus MJ: Common
processes in evidence-based adolescent HIV prevention. Aids Behav.
2008;12:374–383.
69. Malow RM, Kershaw T, Sipsma H, Rosenberg R, Devieux JG. HIV
preventive interventions for adolescents: A look back and ahead. Curr
HIV/AIDS Rep. 2007;4:173–180.
70. Tevendale HD, Lightfoot M: Programs that work: Prevention for
positives. In: Lyon ME, D’Angelo LJ, editors: Teenagers HIV and
AIDS: Insights from youths living with the virus Westport, CT: Praeger
Publishers; 2006, p. 105–126.
71. Lyon ME, Woodward K. Nonstigmatizing ways to engage HIV-positive
African-American teens in mental health and supportive services:
A commentary. J Natl Med Assoc. 2003;95:196–200.
72. US Department of Health and Human Services. Call To Action:
Eliminating racial and ethnic disparities in health. Washington, DC:
Grantmakers in Health; 1998.
73. Dickens DS. Building competence in pediatric end-of-life care. J Palliative
Med. 2009;12(7):617–622.

Dovepress

HIV/AIDS - Research and Palliative Care

Publish your work in this journal
HIV/AIDS - Research and Palliative Care is an international, peerreviewed open-access journal focusing on advances in research in
HIV, its clinical progression and management options including antiviral treatment, palliative care and public healthcare policies to control
viral spread. The journal welcomes original research, basic science,

clinical & epidemiological studies, reviews & evaluations, expert
opinion & commentary, case reports & extended reports. The manuscript management system is completely online and includes a very
quick and fair peer-review system. Visit http://www.dovepress.com/
testimonials.php to read real quotes from published authors.

Submit your manuscript here: http://www.dovepress.com/hivaids---research-and-palliative-care-journal

HIV/AIDS - Research and Palliative Care 2010:2

submit your manuscript | www.dovepress.com

Dovepress

37

